NL-OMON47803
Withdrawn
Phase 3
The Efficacy and Safety of Intra-Arterial Administration of REX-001 to treat ischaemic rest pain in Subjects with Critical Limb Ischaemia Rutherford Category 4 and Diabetes Mellitus: A Pivotal, Placebo Controlled, Double-Blind, Parallel-Group, Adaptive Trial - REX-001-004 Rutherford Category 4
Rexgenero Limited0 sites6 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- peripheral artery disease
- Sponsor
- Rexgenero Limited
- Enrollment
- 6
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged \>\= 18 to \<\= 85 years.
- •2\. Diagnosis of Type I or II DM, established more than one year ago.
- •3\. Glycosylated hemoglobin (HbA1c) \< 9%.
- •4\. Subjects with poor or no (surgical or endovascular) revascularization option, classified as CLI Rutherford Category 4\.
- •The blood circulation in these subjects must be compromised at screening defined as:
- •Ankle systolic pressure \< 50 mm Hg, or
- •Toe systolic pressure \< 30 mm Hg, or
- •Transcutaneous oxygen pressure (tcpO2\) \< 30 mm Hg, and
- •Flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR)
- •The subject should have rest pain without tissue loss, and the rest pain must be persistent and require analgesics for at least two weeks for the subject to be eligible. Subjects with non\-compressible vessels must qualify on toe pressure or tcpO2\.
Exclusion Criteria
- •1\. Advanced CLI defined as presence of major tissue loss (i.e.as significant ulceration and/or gangrene) proximal to the metatarsal heads (CLI Rutherford Category 6\). Significant ulceration/gangrene means any ulceration that extends beyond the subcutaneous tissue layer, or any gangrene or tissue necrosis proximal to the metatarsal heads.
- •2\. CLI Rutherford Category 5\.
- •3\. Uncontrolled or untreated proliferative retinopathy.
- •4\. Failed surgical or endovascular revascularization on the index leg within 10 days prior to screening.
- •5\. Subjects in whom arterial insufficiency in the lower extremity is the result of acute limb ischaemia or an immunological or inflammatory or non\-atherosclerotic disorder (e.g., thromboangiitis obliterans (Buerger\*s Disease), or systemic sclerosis (both limited and diffuse forms).
- •6\. Clinical evidence of invasive infection on index leg defined as major tissue loss at the mid\-foot or heel involving tendon and/or bone, and/or when according to the Investigator intravenous antibiotics are required to treat the infection.
- •7\. At screening, the presence of only neuropathic ulcers on the index leg.
- •8\. Amputation at or above the talus on the index leg.
- •9\. Planned major amputation within the first month after randomization.
- •10\. Subjects who may not be healthy enough to successfully complete all protocol requirements including BM collection, or who are not expected to survive more than 12 months, or in whom results may be particularly difficult to assess, as assessed by the Investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical trial to test the efficacy and safety of intra-arterial administration of REX-001 to treat ischemic ulcers in subjects with critical limb ischaemia Rutherford Category 5 and diabetes mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 21.1 Level: LLT Classification code 10077142 Term: Limb ischemia System Organ Class: 100000004866MedDRA version: 21.1 Level: LLT Classification code 10058069 Term: Critical limb ischemia System Organ Class: 100000004866MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003980-21-HURexgenero Limited78
Active, not recruiting
Phase 1
A clinical trial to test the efficacy and safety of a bone marrow cell preparation to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 19.1Level: LLTClassification code 10077142Term: Limb ischemiaSystem Organ Class: 100000004866MedDRA version: 19.1Level: LLTClassification code 10058069Term: Critical limb ischemiaSystem Organ Class: 100000004866MedDRA version: 19.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-000240-34-NLRexgenero Limited60
Active, not recruiting
Phase 1
A clinical trial to test the efficacy and safety of intra-arterial administration of REX-001 to treat ischaemic ulcers in subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 21.1Level: LLTClassification code 10077142Term: Limb ischemiaSystem Organ Class: 100000004866MedDRA version: 24.0Level: LLTClassification code 10058069Term: Critical limb ischemiaSystem Organ Class: 100000004866MedDRA version: 20.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003980-21-PTRexgenero Limited78
Active, not recruiting
Phase 1
A clinical trial to test the efficacy and safety of a bone marrow cell preparation to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 21.1 Level: LLT Classification code 10077142 Term: Limb ischemia System Organ Class: 100000004866MedDRA version: 21.1 Level: LLT Classification code 10058069 Term: Critical limb ischemia System Organ Class: 100000004866MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-000240-34-PTRexgenero Limited60
Active, not recruiting
Phase 1
A clinical trial to test the efficacy and safety of a bone marrow cell preparation to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 19.1 Level: LLT Classification code 10077142 Term: Limb ischemia System Organ Class: 100000004866MedDRA version: 19.1 Level: LLT Classification code 10058069 Term: Critical limb ischemia System Organ Class: 100000004866MedDRA version: 19.1 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-003980-21-ESRexgenero Limited78